CN103735623A - Auxiliary blood fat reducing tablet - Google Patents
Auxiliary blood fat reducing tablet Download PDFInfo
- Publication number
- CN103735623A CN103735623A CN201410050430.4A CN201410050430A CN103735623A CN 103735623 A CN103735623 A CN 103735623A CN 201410050430 A CN201410050430 A CN 201410050430A CN 103735623 A CN103735623 A CN 103735623A
- Authority
- CN
- China
- Prior art keywords
- parts
- tablet
- blood fat
- test
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses an auxiliary blood fat reducing tablet. The auxiliary blood fat reducing tablet is characterized by mainly comprising the following raw materials in parts by weight: 150-250 parts of red yeast rice powder, 10-50 parts of ginkgo biloba extract, 60-100 parts of a salvia extract, 180-260 parts of microcrystalline cellulose, 50-100 parts of dextrin, and 2-10 parts of magnesium stearate. The auxiliary blood fat reducing tablet has the benefits as follows: the tablet is developed with research results and traditional medicine theory; the red yeast rice powder, the ginkgo biloba extract and the salvia extract are taken as main raw materials to play a comprehensive effect, so as to reduce cholesterol, triglyceride and low-density lipoprotein and raise high-density lipoprotein; the tablet can play a comprehensive blood fat reducing healthcare effect; the tablet is convenient to take and easy to absorb; the product is good in the curative effect; the effective rate in a test-meal group is up to 90%; the tablet is free from any obvious side effects and any toxic or side effects; the tablet is safe, reliable and suitable for long-term taking.
Description
Technical field
The present invention relates to a kind of medicine, be specifically related to a kind of auxiliary antilipemic sheet, belong to medical technical field.
Background technology
Blood fat is the general name of contained lipid material in blood, and the lipid in blood mainly comprises triglyceride, phospholipid, cholesterol and free fatty.Blood fat is a kind of important material in human body, has many very important functions, but can not exceed certain scope, otherwise will cause serious infringement to health.
Hyperlipidemia refers to Blood Cholesterol (TC) and/or triglyceride (TG) is too high or HDL-C (HDL-C) is too low, and modern medicine is referred to as dyslipidemia.At present, domesticly generally with adult's Diagnostic Value of Fasting Serum T-CHOL, exceed 5.72mmol/L, triglyceride exceedes 1.70mmol/L, is diagnosed as hyperlipemia.T-CHOL is called to marginality 5.2～5.7mmol/L person to raise.Abnormalities of sugar/lipid metabolism is the origin of blood matter pathological changes and life decline, is the principal element that causes cardiovascular diseases and endocrinopathy, and human life's health in serious threat.If Hyperlipemia, easily causes " blood is thick ", in blood vessel wall, deposit, forming gradually little speckle (being exactly " atherosclerosis " that we often say) these " specklees " increases, increases, artery-clogging gradually, makes blood flow slack-off, and when serious, blood flow is interrupted.If this situation occurs in heart, just cause coronary heart disease; Occur in brain, just there will be apoplexy; If obstruction optical fundus blood vessel, will cause visual deterioration, blind; If occur in kidney, will cause renal arteriosclerosis, renal failure; Occur in lower limb, there will be limb necrosis, fester etc.In addition, hyperlipidemia can cause hypertension, brings out cholelithiasis, pancreatitis, increases the weight of hepatitis, causes male sexual disorder, the disease such as senile dementia.
Current research prompting hyperlipidemia may be relevant with the morbidity of cancer.
In summary, hyperlipidemia has been the Major Risk Factors beyond generally acknowledged hypertension, coronary heart disease and cerebrovascular, all closely related with a lot of serious diseases.
The medicine of at present common blood fat reducing has:
1. cholic acid integrated agent: the common blood fat reducing mechanism of this class medicine is to stop cholic acid or cholesterol from intestinal absorption, promotes cholic acid or cholesterol to discharge with feces, promotes the degraded of cholesterol.This class medicine mainly contains resinae, neomycin class, sitoesterol and active carbon etc.But this class preparation side effect is many especially, is difficult to adhere to for a long time taking.
2. hydrochloric acid and derivant thereof: it is the formation that suppresses cAMP that hydrochloric acid regulates the main mechanism of blood fat, cause triglyceride enzymatic activity to reduce, lipolysis in fatty tissue slows down, the lowering of concentration of non-esterified fatty acid in blood (NEFA), the synthetic VLDL of liver reduces, and further makes IDL and LDL also reduce.In addition, hydrochloric acid can synthesize nitocinoylglycine with glycine under the effect of coenzyme A (CoA), thereby hinder hepatocyte, utilizes CoA contract cholesterol.But this type of medicine has serious side effect: make peptic ulcer activation, can increase the weight of Peptic Ulcers; Make impaired glucose tolerance, thereby diabetes are increased the weight of; Blood uric acid is increased, even cause gout, liver function damage etc.
3. statins: the mechanism of action of this class medicine is to suppress HMG-CoA reductase by the competition of hydroxy-methyl-glutaryl coenzyme A (HMG-CoA) reversibility, effectively reduce or block synthesizing of body inner cholesterol, thereby feedback irritation cell film surface (being mainly hepatocyte) low density lipoprotein, LDL (LDL) acceptor quantity and active increase, make serum cholesterol remove increase, level reduction.But, in clinical practice, to find, this class medicine can cause gravis, and especially, when large dose oral administration, situation is even more serious.
Because the product of above blood fat reducing class all has larger side effect, simultaneously can not long-term taking, therefore there has been now the health food of some common auxiliary antilipemics on market, particular type is as follows:
1, linoleic acid: linoleic acid and gamma-Linolenic acid are bivalence unsaturated fatty acids, and human body self can not synthesize, must be by dietetic feeding, essential fatty acid be therefore called again.Linoleic acid can be combined into ester with cholesterol, thereby be then degraded to cholic acid, excrete and can reduce cholesterol in blood plasma.Their content in Animal fat is less, and in sunflower oil, Semen Maydis oil, safflower oil, Radix Oenotherae erythrosepalae oil, content is higher.But effect for reducing fat a little less than, be often made into compound preparation application, be applicable to slight hyperlipemia.
2, polyunsaturated fatty acid class: polyunsaturated fatty acid is trivalent unsaturated fatty acid, is also essential fatty acid, comprises alpha-linolenic acid, DHA, EPA, and wherein DHA and EPA are changed into by alpha-linolenic acid.Alpha-linolenic acid content in Caulis et Folium Lini (linum), Folium Perillae, Fructus Hippophae is higher, is also present in some algae.DHA and EPA are present in some marine organisms, at present main how extraction from marine fishes.This class preparation is more paid attention to compared with linoleic acid at present.Wherein bathypelagic fish oil is natural medicine, effective to hyperlipemia, and untoward reaction is few, but is generally used for soft capsule dosage form.
3, lecithin: lecithin and hydrolyzate choline thereof have affinity and emulsification to fat, can promote fatty metabolism, and it is excreted, prevents fat abnormal stacking in vivo.It should be noted that lecithin has diuresis, therefore, is not very suitable this series products in dry season.
To sum up aforementioned, various Experimental agents or health food in the market all have various shortcoming to blood fat reducing, can not meet the long-term taking requirement of people with hyperlipidemia.
Summary of the invention
For solving the deficiencies in the prior art, the object of the present invention is to provide that a kind of brand-new side effect is little, better efficacy, take auxiliary antilipemic sheet more easily.
In order to realize above-mentioned target, the present invention adopts following technical scheme:
A kind of auxiliary antilipemic sheet, is characterized in that, mainly the raw material of following weight portion, consists of:
Aforesaid auxiliary antilipemic sheet, is characterized in that, mainly the raw material of following weight portion, consists of:
Aforesaid auxiliary antilipemic sheet, is characterized in that, mainly the raw material of following weight portion, consists of:
Aforesaid auxiliary antilipemic sheet, is characterized in that, mainly the raw material of following weight portion, consists of:
Aforesaid auxiliary antilipemic sheet, is characterized in that, mainly the raw material of following weight portion, consists of:
Aforesaid auxiliary antilipemic sheet, is characterized in that, mainly the raw material of following weight portion, consists of:
Usefulness of the present invention is: take Hongqu powder (red colouring agent), Folium Ginkgo extract, Radix Salviae Miltiorrhizae extract as primary raw material, with modern study achievement, in conjunction with traditional medical theory, develop, three share, effect is comprehensive, to reducing cholesterol, triglyceride, low density lipoprotein, LDL, high density lipoprotein increasing all has certain effect, and has the health-care effect of comprehensive blood fat reducing; Make tablet, taking convenience, easily absorption; Product good effect, test-meal group effective percentage can be up to 90%; Have no obvious adverse reaction and occur, product is without any side effects, safe and reliable, is applicable to long-term taking.
The specific embodiment
Scientific researches prove in a large number, and Chinese herbal medicine is better to the experiment effect of hyperlipemia.Chinese herbal medicine can be from every physiological function of the comprehensive conditioning human body of different internal organs different angles, experiment of TCM dyslipidemia not only stable curative effect, lasting, compliance is good, and body is had no side effect, also can prevent simultaneously and improve the common various multiple diseases of middle-aged and elderly people, thereby more and more be subject to the favor of consumer.
Effective ingredient is resolved:
Hongqu powder (red colouring agent)
Hongqu powder (red colouring agent) is the natural statin substance that utilizes rice fermentation to obtain, and has the effect of obvious adjusting blood fat.Monas cuspurpureus Went is of long standing and well established in Chinese application, being the greatness invention of China ancestor wonderful workmanship excelling nature, is the science and culture legacy of motherland's preciousness, and Monas cuspurpureus Went is exactly the good merchantable brand that also polyphagia with emaciation is cured since ancient times, on Yunnan Province of China and other places, the custom of the material that just has edible this rice fermentation among the people.Medicinal and other purposes are all on the books to it in < < Compendium of Materia Medica > >, < < Tian Gong Kai Wu > >.Traditional medicine thinks that Monas cuspurpureus Went is warm in nature, sweet in the mouth, has the effect of blood circulation promoting and blood stasis dispelling, strengthening the spleen to promote digestion.
Modern study shows that Monas cuspurpureus Went has the pharmacological actions widely such as blood fat reducing, blood pressure lowering, blood sugar lowering, antitumor, resisting fatigue, enhancing immunity.Lovastatin in Monas cuspurpureus Went is the main composition of its effect for reducing blood fat, large quantity research shows that lovastatin is the specific inhibitor of body inner cholesterol synzyme HMG-CoA reductase, thereby reduce the synthetic of cholesterol by suppressing HMG-CoA reductase, thereby remarkable to serum cholesterol reducing effect, and there is the effect that reduces triglyceride and low-density lipoprotein cholesterol and high density lipoprotein increasing cholesterol.This natural statin substance in Hongqu powder (red colouring agent) is active open loop structure, human body can directly absorb, can not produce toxic and side effects to liver, kidney and muscle, experimental results show that, natural statin substance regulates the effect of blood fat same with chemical statin substance remarkable, safety is far better than chemical statin substance, because chemical statin substance is closed-loop structure compound, must be converted into the activated open loop structure of tool by liver, conversion process produces material toxic side effect, can damage liver, kidney and muscle.
Folium Ginkgo extract
Folium Ginkgo extract extracts from Folium Ginkgo.Folium Ginkgo is the dried leaves of Ginkgoaceae plant Ginkgo biloba Ginkgo biloba L..Folium Ginkgo is flat, sweet in the mouth, hardship, puckery, GUIXIN, lung meridian.There is blood circulation promoting and blood stasis dispelling, change turbid blood fat reducing, removing obstruction in the collateral to relieve pain, the effect of relievining asthma of astringing the lung.For obstruction of collaterals by blood stasis, obstruction of qi in the chest and cardialgia, apoplectic hemiplegia, cough and asthma due to lung deficiency, hyperlipemia.
Folium Ginkgo is rich in Flavonoid substances, also contain in addition bilobalide etc., the flavone compound of Folium Ginkgo and bilobalide have the cardiovascular and cerebrovascular disease that anti-high heart and brain blood fat causes, with health role to cardiovascular and cerebrovascular vessel, also have other multiple higher pharmacological actions simultaneously.Modern pharmacological research shows that Folium Ginkgo extract can make blood T-CHOL, triglyceride reduce, and high density lipoprotein raises.Folium Ginkgo extract has vessel softening, prevents and treats arteriosclerosis, removes fatty rubbish in blood, suppresses platelet aggregation, prevents and treats the good action that brain bolt forms.Clinical trial also confirms that Folium Ginkgo or extract formulation and related activity composition thereof, regulating lipid aspects to have significant effect, are described as " cardiovascular protection god ".
Radix Salviae Miltiorrhizae extract
Radix Salviae Miltiorrhizae extract extracts from Radix Salviae Miltiorrhizae.Radix Salviae Miltiorrhizae is dry root and the rhizome of labiate Radix Salviae Miltiorrhizae Salvia miltiorrhizaBge..Radix Salviae Miltiorrhizae cold nature, bitter in the mouth, GUIXIN, Liver Channel, have blood circulation promoting and blood stasis dispelling, inducing menstruation to relieve menalgia, the relieving restlessness that clears away heart-fire, the effect of removing heat from blood eliminating carbuncle.
Radix Salviae Miltiorrhizae can effectively be removed the blood fat precipitation in blood vessel wall; Vessel softening, suppresses endogenous cholesterol synthetic, reduces neutral fat, suppresses platelet aggregation, reduce plasma viscosity, coronary artery dilator, increases blood flow coronarius, alleviate the myocardial damage that anoxia causes, accelerate velocity of blood flow, expansion blood flow, improve microcirculation etc.Modern study shows that Radix Salviae Miltiorrhizae can make cholesterol (TC), triglyceride (TG) and low density lipoprotein, LDL (LDL) reduce.
Each component can be bought and obtain on market above.
The present invention, take Hongqu powder (red colouring agent), Folium Ginkgo extract, Radix Salviae Miltiorrhizae extract as primary raw material, develops in conjunction with traditional medical theory with modern study achievement.Three share, and effect is comprehensive, and to reducing cholesterol, triglyceride, low density lipoprotein, LDL, high density lipoprotein increasing all has certain effect, and has the health-care effect of comprehensive blood fat reducing.
The present invention also meets traditional theory of medicine, and the each raw material of the present invention is not at the row of " eighteen incompatible medicaments ", " nineteen medicaments of mutual restraint ", without incompatibility.The traditional Chinese medical science thinks that hyperlipidemia is that expectorant holds in turbid, the venation stasis of blood is stagnant, and experiment is when resolving phlegm lowering turbidity, promoting blood circulation to remove obstruction in the collateral.Traditional medicine thinks that Monas cuspurpureus Went is warm in nature, and sweet in the mouth is returned liver, spleen, large intestine channel, has the effect of strengthening the spleen to promote digestion, blood circulation promoting and blood stasis dispelling, and spleen is strong can make water paddy with eating with change, and phlegm-damp is raw, is to radically reform; Folium Ginkgo is flat, sweet in the mouth, hardship, puckery, and GUIXIN, lung meridian, have blood circulation promoting and blood stasis dispelling, changes turbid blood fat reducing, removing obstruction in the collateral to relieve pain, the effect of relievining asthma of astringing the lung, for obstruction of collaterals by blood stasis, obstruction of qi in the chest and cardialgia, apoplectic hemiplegia, cough and asthma due to lung deficiency, hyperlipemia; Radix Salviae Miltiorrhizae cold nature, bitter in the mouth, GUIXIN, Liver Channel, have blood circulation promoting and blood stasis dispelling, inducing menstruation to relieve menalgia, the relieving restlessness that clears away heart-fire, the effect of removing heat from blood eliminating carbuncle.Three share, gentle and not inclined to one side, and by strengthening the spleen to promote digestion, blood stasis dispelling blood fat reducing, changes turbid blood fat reducing, blood activating and fat reducing and beat altogether auxiliary lipid-lowering efficacy.
Hongqu powder (red colouring agent) is the natural statin substance that utilizes rice fermentation to obtain, and Folium Ginkgo extract and Radix Salviae Miltiorrhizae extract belong to the article that can be used for health food, and each raw material all has no side effect, can long-term taking, and safe and effective.
Below in conjunction with specific embodiment, the present invention is done to concrete introduction.
Embodiment 1
155 parts of Hongqu powder (red colouring agent)s, 31 parts of Folium Ginkgo extract, 78 parts of Radix Salviae Miltiorrhizae extracts, 236 parts of microcrystalline Cellulose, 94.5 parts, dextrin, 5.5 parts of magnesium stearate, unit is weight portion.
Make the tablet that taking convenience easily absorbs, operational approach is: sieve, weigh, mix, soft material processed, granulation, dry, granulate, always mix, tabletting.
Embodiment 2
185 parts of Hongqu powder (red colouring agent)s, 28 parts of Folium Ginkgo extract, 85 parts of Radix Salviae Miltiorrhizae extracts, 212 parts of microcrystalline Cellulose, 79.5 parts, dextrin, 10.5 parts of magnesium stearate, unit is weight portion.
Make the tablet that taking convenience easily absorbs, its operational approach is: sieve, weigh, mix, soft material processed, granulation, dry, granulate, always mix, tabletting.
Embodiment 3
195 parts of Hongqu powder (red colouring agent)s, 24 parts of Folium Ginkgo extract, 81 parts of Radix Salviae Miltiorrhizae extracts, 225 parts of microcrystalline Cellulose, 70.5 parts, dextrin, 4.5 parts of magnesium stearate, unit is weight portion.
Make the tablet that taking convenience easily absorbs, its operational approach is: sieve, weigh, mix, soft material processed, granulation, dry, granulate, always mix, tabletting.
Embodiment 4
225 parts of Hongqu powder (red colouring agent)s, 16 parts of Folium Ginkgo extract, 71 parts of Radix Salviae Miltiorrhizae extracts, 233 parts of microcrystalline Cellulose, 50.5 parts, dextrin, 4.5 parts of magnesium stearate, unit is weight portion.
Make the tablet that taking convenience easily absorbs, its operational approach is: sieve, weigh, mix, soft material processed, granulation, dry, granulate, always mix, tabletting.
Embodiment 5
245 parts of Hongqu powder (red colouring agent)s, 12 parts of Folium Ginkgo extract, 63 parts of Radix Salviae Miltiorrhizae extracts, 199 parts of microcrystalline Cellulose, 71 parts, dextrin, 10 parts of magnesium stearate, unit is weight portion.
Make the tablet that taking convenience easily absorbs, its operational approach is: sieve, weigh, mix, soft material processed, granulation, dry, granulate, always mix, tabletting.
Curative effect test
Adopt two kinds of control design between self and group, according to the requirement of random-blind method, the non-110 examples hyperlipidemia experimenters that are in hospital are divided into test-meal group and matched group, each 55 examples of test-meal group and matched group at random.Viewing duration diet and living habit are constant, and test-meal group is taken product of the present invention (comprising embodiment 1 to embodiment 5 preparation-obtained product).Take and after 30 days, observe that it is general
Situation and efficiency index.
1, ordinary circumstance and status of blood lipid comparison before test-meal:
Observe altogether 110 examples, wherein effective case 103 examples.
Test-meal group male 27 examples, women's 24 examples, minimum 30 years old of age, the oldest 64 years old, average 48.61 years old;
Matched group male 28 examples, women's 24 examples, minimum 30 years old of age, maximum 63 years old, average 46.73 years old.
The front two groups of experimenter's Abdominal B type ultrasonography of test-meal, electrocardiogram, x-ray fluoroscopy of chest detect, all in normal range.
Status of blood lipid and ordinary circumstance comparison before table 1 test-meal
From table 1, before test-meal, relatively indices no significant difference (P > 0.05) of test-meal group and matched group status of blood lipid and ordinary circumstance, has comparability, and two groups have harmony.
2, safety indexes comparison before and after test-meal:
(1) ordinary circumstance comparison: the no abnormality seens such as two groups of front and back of test-meal experimenter's spirit, sleep, diet, body weight, defecation, blood pressure, heart rate.
(2) the index comparison such as two groups of experimenter's blood, urine, feces, liver function, kidney merit before and after test-meal
Table 2 experimenter tests forward and backward index of correlation comparison
From table 2, the indices such as the two groups of experimenters' in test-meal front and back blood, urine, feces routine examination and liver, kidney function test are all in normal range.
Efficiency index comparison before and after 3 test-meals:
(1) two groups of experimenter's serum total cholesterols comparison before and after test-meal
The impact of table 3 product of the present invention on serum total cholesterol (TC) (mmol/L,
)
Note: level comparison: * * P < 0.01 before and after self; Level comparison between test-meal group and matched group group: ##P < 0.01.
From table 3, before and after test-meal, test-meal group self relatively serum total cholesterol reduces by 0.88 ± 0.31mmol/L, and rate of descent is 11.40 ± 3.76%, and difference has significance (P < 0.01); Matched group self is serum total cholesterol no significant difference (P > 0.05) relatively.Between group, compare test-meal group serum total cholesterol no significant difference (P > 0.05) compared with matched group before test-meal; After test-meal, test-meal group serum total cholesterol compared with matched group obviously reduces, and difference has significance (P < 0.01).
(2) two groups of experimenter's triglyceride comparison before and after test-meal
The impact of table 4 product of the present invention on triglyceride (TG) (mmol/L,
)
Note: level comparison: * * P < 0.01 before and after self; Level comparison between test-meal group and matched group group: ##P < 0.01.
From table 4, before and after test-meal, test-meal group self relatively triglyceride reduces by 0.54 ± 0.28mmol/L, and rate of descent is 16.08 ± 6.30%, and difference has significance (P < 0.01); Matched group self is triglyceride no significant difference (P > 0.05) relatively.Between group, compare test-meal group triglyceride no significant difference (P > 0.05) compared with matched group before test-meal; After test-meal, test-meal group triglyceride compared with matched group obviously reduces, and difference has significance (P < 0.01).
(3) two groups of experimenter's HDL-C comparison before and after test-meal
Table 5 product of the present invention is to HDL-C (HDL-C)
Impact (mmol/L,
)
Note: level comparison between test-meal group and matched group group: #P < 0.01.
From table 5, test-meal group self is compared High-density Lipoprotein-cholesterol and is slightly raise, but zero difference has significance (P > 0.05); Matched group self is HDL-C no significant difference (P > 0.05) relatively.Between group, relatively, there are no significant (P < 0.05) for the forward and backward HDL-C difference of test-meal.
(4) experimenter's serum TC, TG, HDL-C effective percentage and total effective rate after test-meal
Table 6 serum TC, TG, HDL-C effective percentage and total effective rate
With relatively ##P < 0.0l of matched group, #P < 0.05; Through X2 check, two groups of total effective rates have significant difference, P < 0.0l.
Test-meal result shows, after test-meal, test-meal group serum total cholesterol (TC) is compared with the 0.88 ± 0.31mmol/L that declined before test-meal, and rate of descent is 11.40 ± 3.76%; Triglyceride (TG) 0.54 ± 0.28mmol/L that declined, rate of descent is 16.08 ± 6.30%, and HDL-C (HDL-C) is not significantly lower than matched group; Between TC, test-meal group self comparison of TG binomial index and test-meal group and matched group group, relatively, difference has significance (P < 0.01), and reaches effective criterion; The indices such as test-meal front and back examination trencherman's general status and blood, urine, feces routine examination and liver, kidney function test are all in normal range.
Test-meal group effective percentage can be up to 90%, points out product curative effect of the present invention better.
In addition, have no obvious adverse reaction and occur, illustrate that product of the present invention is without any side effects, safe and reliable, can long-term taking.
It should be noted that, above-described embodiment does not limit the present invention in any form, and all employings are equal to replaces or technical scheme that the mode of equivalent transformation obtains, all drops in protection scope of the present invention.
Claims (6)
1. auxiliary antilipemic sheet, is characterized in that, mainly the raw material of following weight portion, consists of:
2. auxiliary antilipemic sheet according to claim 1, is characterized in that, mainly the raw material of following weight portion, consists of:
3. auxiliary antilipemic sheet according to claim 1, is characterized in that, mainly the raw material of following weight portion, consists of:
4. auxiliary antilipemic sheet according to claim 1, is characterized in that, mainly the raw material of following weight portion, consists of:
5. auxiliary antilipemic sheet according to claim 1, is characterized in that, mainly the raw material of following weight portion, consists of:
6. auxiliary antilipemic sheet according to claim 1, is characterized in that, mainly the raw material of following weight portion, consists of:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410050430.4A CN103735623A (en) | 2014-02-13 | 2014-02-13 | Auxiliary blood fat reducing tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410050430.4A CN103735623A (en) | 2014-02-13 | 2014-02-13 | Auxiliary blood fat reducing tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103735623A true CN103735623A (en) | 2014-04-23 |
Family
ID=50492738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410050430.4A Pending CN103735623A (en) | 2014-02-13 | 2014-02-13 | Auxiliary blood fat reducing tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103735623A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105124569A (en) * | 2015-07-13 | 2015-12-09 | 北京世纪合辉医药科技股份有限公司 | Blood-fat-reducing health-caring food and preparation method of same |
| CN106491706A (en) * | 2016-11-03 | 2017-03-15 | 云南中科本草科技有限公司北京分公司 | Ginkgo leaf capsule of red sage root |
| CN109619586A (en) * | 2019-01-24 | 2019-04-16 | 山西潞安石圪节智华生物科技有限公司 | A kind of peony seed oil blood fat reducing preparation and preparation method thereof |
| CN113730547A (en) * | 2021-09-17 | 2021-12-03 | 江苏协合转化医学研究院有限公司 | Composition for reducing blood fat and dissolving thrombus, preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1593585A (en) * | 2004-06-24 | 2005-03-16 | 无锡健特药业有限公司 | Blood fat regulating healthy product |
| CN101524422A (en) * | 2009-04-20 | 2009-09-09 | 无锡健特药业有限公司 | Health products with hypolipemic function, preparation method and usage thereof |
-
2014
- 2014-02-13 CN CN201410050430.4A patent/CN103735623A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1593585A (en) * | 2004-06-24 | 2005-03-16 | 无锡健特药业有限公司 | Blood fat regulating healthy product |
| CN101524422A (en) * | 2009-04-20 | 2009-09-09 | 无锡健特药业有限公司 | Health products with hypolipemic function, preparation method and usage thereof |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105124569A (en) * | 2015-07-13 | 2015-12-09 | 北京世纪合辉医药科技股份有限公司 | Blood-fat-reducing health-caring food and preparation method of same |
| CN106491706A (en) * | 2016-11-03 | 2017-03-15 | 云南中科本草科技有限公司北京分公司 | Ginkgo leaf capsule of red sage root |
| CN109619586A (en) * | 2019-01-24 | 2019-04-16 | 山西潞安石圪节智华生物科技有限公司 | A kind of peony seed oil blood fat reducing preparation and preparation method thereof |
| CN109619586B (en) * | 2019-01-24 | 2022-02-22 | 山西潞安矿业(集团)有限责任公司 | Peony seed oil blood fat reducing preparation and preparation method thereof |
| CN113730547A (en) * | 2021-09-17 | 2021-12-03 | 江苏协合转化医学研究院有限公司 | Composition for reducing blood fat and dissolving thrombus, preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101091708A (en) | Composition for reducing blood fat, and preparation method | |
| CN103735623A (en) | Auxiliary blood fat reducing tablet | |
| CN1857458A (en) | Health product and medicine and their preparing method | |
| CN106234635A (en) | A kind of for Camellia oil regulating blood fat and preparation method thereof | |
| CN102038778B (en) | Chinese medicinal composition with effects of relaxing meridians, activating collaterals, expelling wind and removing dampness and preparation method thereof | |
| CN106729123A (en) | A kind of composition of three high drop and preparation method thereof | |
| CN103736071A (en) | Composition having effect of assisting in decreasing blood sugar, and application and preparation method thereof | |
| CN1738633A (en) | Anti-obesity ingretients from medicinal plants and their composittion | |
| CN105169093A (en) | Composition for conditioning blood fat and blood pressure and preparation method thereof | |
| CN103735603B (en) | A kind of compound antihyperglycemic soft capsule and preparation method thereof | |
| CN102526639A (en) | Chinese medicinal composition for treating hyperlipidemia and preparation method thereof | |
| CN102552743A (en) | Medicinal composition for treating diabetes and preparation method thereof | |
| CN112089784A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis | |
| CN102205010A (en) | Pharmaceutical composition with auxiliary function of reducing blood fat | |
| CN102698185B (en) | Traditional Tibetan medicine for treating hyperlipidemia and preparation method thereof | |
| CN101002804A (en) | Pure natural preparations used as depressor and hypolipidemic, and preparing method thereof | |
| CN1299732C (en) | Chinese medicine preparation for treating fatty liver | |
| CN101647845B (en) | Natural product composition used for reducing blood fat and preparation method thereof | |
| CN1660207A (en) | Preparation of health care for reducing blood fat and cholesterol, and producing method | |
| CN104784659A (en) | Traditional Chinese medicine tablet for treating hyperlipidemia and preparation method thereof | |
| CN104288566A (en) | Traditional Chinese medicine composition for reducing cholesterol and/or reducing blood lipids as well as preparation method and application of traditional Chinese medicine composition | |
| CN1293914C (en) | Health care medicinal composition for improving sleeping and preparation preocess thereof | |
| CN112089783B (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity | |
| CN102228661B (en) | Chinese medicinal cholecystitis treatment mixture for treating chronic cholecystitis | |
| CN1181875C (en) | Medicine for curing fat liver of obesity and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140423 |
|
| RJ01 | Rejection of invention patent application after publication |